Hemerion Therapeutics

📍 Lille, France🗓 Founded 2020👥 16 employees💰 Last funded Apr 2022
Biotechnology Research🌐 hemerion.com
Website LinkedIn
Hemerion is a clinical stage HealthTech company. Its first breakthrough technology jointly designed with University of Lille, Inserm and University Hospital of Lille, addresses brain cancer and aims to help patients in their fight against glioblastoma. Hemerion results of over 10 years of leading academic and clinical researches on innovative approaches to treat Glioblastoma. Today, Hemerion owns a unique and disruptive technology, already evaluated in frontline approach to treat patients harboring brain cancer.
2
Total investors
2
Early stage
0
Mid stage
0
Late stage
2020
Founded

Investors

2 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
France
2
Frequently asked questions
Who invested in Hemerion Therapeutics?
Hemerion Therapeutics has 2 investors on record on gritt.io, including 2 early-stage backers.
When did Hemerion Therapeutics last raise funding?
The most recent investment in Hemerion Therapeutics recorded on gritt.io was in April 2022.
When was Hemerion Therapeutics founded?
Hemerion Therapeutics was founded in 2020.
What industry is Hemerion Therapeutics in?
Hemerion Therapeutics operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is Hemerion Therapeutics based?
Hemerion Therapeutics is headquartered in Lille, France.